NBI-1117570

NBI-1117570 is an investigational, oral, small molecule drug that acts as a selective dual agonist of the muscarinic acetylcholine receptors M1 and M4. These receptors are fundamental to activating signaling pathways in the brain, with M1 implicated in cognition and M4 in psychosis. The compound was discovered by Sosei Heptares (now Nxera Pharma) using structure-based drug design and is being developed by Neurocrine Biosciences for the potential treatment of neurological and neuropsychiatric conditions, including symptoms of psychosis and cognitive impairment. As a first-in-class agent targeting both M1 and M4 subtypes selectively, it may offer therapeutic benefits across a range of central nervous system disorders[1][2][3][4][5].

Other names

Dual Muscarinic M1/M4 agonist